GlassScriptPhysician profile
Kaci C Newlin
NPI 1194333849
$6,232.64
in general payments reported to CMS, 2019-2025
29 companies · $995 in 2025
The $995 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,063 · 2022: $1,384 · 2023: $1,503 · 2024: $1,287 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,785.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $709.21 | 2021-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $676.77 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $667.25 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $609.55 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $458.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $372.69 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $351.48 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $273.24 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $268.31 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $251.44 | 2021-2023 | Ultomiris |
| Travere Therapeutics, INC. | $246.03 | 2023-2025 | |
| Horizon Therapeutics Plc | $199.17 | 2021-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $167.39 | 2024-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $148.86 | 2022-2025 | Vafseo, Auryxia |
| Daiichi Sankyo INC. | $136.78 | 2021-2024 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $105.69 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $90.45 | 2022-2023 | Amvuttra |
| Ani Pharmaceuticals, INC. | $77.91 | 2022-2023 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $75.76 | 2022-2023 | Xarelto |
| Opko Pharmaceuticals, LLC | $69.77 | 2022 | |
| Kyowa Kirin, INC. | $66.66 | 2023-2024 | Crysvita |
| Apellis Pharmaceuticals, INC. | $46.34 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $36.97 | 2021 | |
| Ardelyx, INC. | $33.36 | 2024 | Ibsrela |
| Lilly USA, LLC | $32.76 | 2024 | Jardiance |
| Pharmacosmos Therapeutics INC. | $19.27 | 2021 | |
| Scpharmaceuticals INC. | $17.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2022 | |
| Rigel Pharmaceuticals, INC. | $8.11 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaci Newlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.